The SUMO protease SENP6 is a direct regulator of PML nuclear bodies

Molecular Biology of the Cell

Volumn 22, Issue 1, 2011, Pages 78-90

  Hattersley, Neil ^a   Shen, Linnan ^a   Jaffray, Ellis G ^a   Hay, Ronald T ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN SENP6; PROTEINASE; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS INCLUSION BODY; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG ACCUMULATION; IMMUNOFLUORESCENCE; MUTATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN MODIFICATION;

CATALYTIC DOMAIN; CELL NUCLEUS STRUCTURES; CELL SURVIVAL; CYSTEINE; CYSTEINE ENDOPEPTIDASES; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELLS; HUMANS; MUTATION; NUCLEAR PROTEINS; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 78651084831     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E10-06-0504     Document Type: Article

References (77)

1. Ayaydin F, Dasso M (2004). Distinct in vivo dynamics of vertebrate SUMO paralogues. Mol Biol Cell 15, 5208-5218.
2. Bailey D, O'Hare P (2002). Herpes simplex virus 1 ICP0 co-localizes with a SUMO-specific protease. J Gen Virol 83, 2951-2964.
3. Bailey D, O'Hare P (2004). Characterization of the localization and proteolytic activity of the SUMO-specific protease, SENP1. J Biol Chem 279, 692-703.
4. Bailey D, O'Hare P (2005). Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling. Biochem J 392, 271-281.
5. Bernardi R, Pandolfi PP (2007). Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8, 1006-1016. (Pubitemid 350174636)
6. Best JL, Ganiatsas S, Agarwal S, Changou A, Salomoni P, Shirihai O, Meluh PB, Pandolfi PP, Zon LI (2002). SUMO-1 protease-1 regulates gene transcription through PML. Mol Cell 10, 843-855.
7. Boddy MN, Howe K, Etkin LD, Solomon E, Freemont PS (1996). PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13, 971-982.
8. Boisvert FM, Hendzel MJ, Bazett-Jones DP (2000). Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. J Cell Biol 148, 283-292.
9. Bylebyl GR, Belichenko I, Johnson ES (2003). The SUMO isopeptidase Ulp2 prevents accumulation of SUMO chains in yeast. J Biol Chem 278, 44113-44120.
10. Choi SJ, Chung SS, Rho EJ, Lee HW, Lee MH, Choi HS, Seol JH, Baek SH, Bang OS, Chung CH (2006). Negative modulation of RXRalpha transcriptional activity by small ubiquitin-related modifier (SUMO) modification and its reversal by SUMO-specific protease SUSP1. J Biol Chem 281, 30669-30677.
11. Dellaire G, Ching RW, Dehghani H, Ren Y, Bazett-Jones DP (2006). The number of PML nuclear bodies increases in early S phase by a fission mechanism. J Cell Sci 119, 1026-1033.
12. Desterro JM, Rodriguez MS, Hay RT (1998). SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell 2, 233-239.
13. Di Bacco A, Gill G (2006). SUMO-specific proteases and the cell cycle. An essential role for SENP5 in cell proliferation. Cell Cycle 5, 2310-2313.
14. Di Bacco A, Ouyang J, Lee HY, Catic A, Ploegh H, Gill G (2006). The SUMO-specific protease SENP5 is required for cell division. Mol Cell Biol 26, 4489-4498.
15. Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, Solomon E, de Thé H, Hay RT, Freemont PS (1999). SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci 112 (Pt 3), 381-393.
16. Eskiw CH, Dellaire G, Bazett-Jones DP (2004). Chromatin contributes to structural integrity of promyelocytic leukemia bodies through a SUMO-1-independent mechanism. J Biol Chem 279, 9577-9585.
17. Eskiw CH, Dellaire G, Mymryk JS, Bazett-Jones DP (2003). Size, position and dynamic behavior of PML nuclear bodies following cell stress as a paradigm for supramolecular trafficking and assembly. J Cell Sci 116, 4455-4466. (Pubitemid 37369600)
18. Evdokimov E, Sharma P, Lockett SJ, Lualdi M, Kuehn MR (2008). Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3. J Cell Sci 121, 4106-4113.
19. Fu C et al. (2005). Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3. Oncogene 24, 5401-5413.
20. Geoffroy M-C, Jeffray EG, Walker KJ, Hay RT (2010). Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Mol Biol Cell 21, 4227-4239.
21. Gong L, Yeh ET (2006). Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem 281, 15869-15877.
22. Gustafsson MG (2008). Super-resolution light microscopy goes live. Nat Methods 5, 385-387.
23. Haindl M, Harasim T, Eick D, Muller S (2008). The nucleolar SUMO-specific protease SENP3 reverses SUMO modification of nucleophosmin and is required for rRNA processing. EMBO Rep 9, 273-279.
24. Han Y et al. (2010). SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J Biol Chem 285, 12906-12915.
25. Hang J, Dasso M (2002). Association of the human SUMO-1 protease SENP2 with the nuclear pore. J Biol Chem 277, 19961-19966. (Pubitemid 34967518)
26. Hannich JT, Lewis A, Kroetz MB, Li SJ, Heide H, Emili A, Hochstrasser M (2005). Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J Biol Chem 280, 4102-4110.
27. Hecker CM, Rabiller M, Haglund K, Bayer P, Dikic I (2006). Specification of SUMO1- and SUMO2-interacting motifs. J Biol Chem 281, 16117-16127.
28. Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, Kamitani T, Yeh ET, Strauss JF, 3rd, Maul GG (1999). PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147, 221-234.
29. Itahana Y, Yeh ET, Zhang Y (2006). Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol 26, 4675-4689.
30. Jensen K, Shiels C, Freemont PS (2001). PML protein isoforms and the RBCC/TRIM motif. Oncogene 20, 7223-7233.
31. Kamitani T, Kito K, Nguyen HP, Wada H, Fukuda-Kamitani T, Yeh ET (1998a). Identification of three major sentrinization sites in PML. J Biol Chem 273, 26675-26682. (Pubitemid 28471682)
32. Kamitani T, Nguyen HP, Kito K, Fukuda-Kamitani T, Yeh ET (1998b). Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J Biol Chem 273, 3117-3120.
33. Koken MH et al. (1994). The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 13, 1073-1083.
34. Kuo ML, den Besten W, Thomas MC, Sherr CJ (2008). Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3. Cell Cycle 7, 3378-3387.
35. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, de Thé H (2008). Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10, 547-555.
36. Lallemand-Breitenbach V et al. (2001). Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 193, 1361-1371.
37. Lang M et al. (2010). Three-dimensional organization of promyelocytic leukemia nuclear bodies. J Cell Sci 123, 392-400.
38. Li SJ, Hochstrasser M (2000). The yeast ULP2 (SMT4) gene encodes a novel protease specific for the ubiquitin-like Smt3 protein. Mol Cell Biol 20, 2367-2377.
39. Li X et al. (2008). SENP1 mediates TNF-induced desumoylation and cytoplasmic translocation of HIPK1 to enhance ASK1-dependent apoptosis. Cell Death Differ 15, 739-750.
40. Lima CD, Reverter D (2008). Structure of the human SENP7 catalytic domain and poly-SUMO deconjugation activities for SENP6 and SENP7. J Biol Chem 283, 32045-32055.
41. Lin FM, Lai YJ, Shen HJ, Cheng YH, Wang TF (2010). Yeast axial-element protein, Red1, binds SUMO chains to promote meiotic interhomologue recombination and chromosome synapsis. EMBO J 29, 586-596.
42. Matafora V, D'Amato A, Mori S, Blasi F, Bachi A (2009). Proteomic analysis of nucleolar SUMO-1 target proteins upon proteasome inhibition. Mol Cell Proteomics 8, 2243-2255.
43. Matic I, van Hagen M, Schimmel J, Macek B, Ogg SC, Tatham MH, Hay RT, Lamond AI, Mann M, Vertegaal AC (2008). In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol Cell Proteomics 7, 132-144.
44. Mukhopadhyay D, Arnaoutov A, Dasso M (2010). The SUMO protease SENP6 is essential for inner kinetochore assembly. J Cell Biol 188, 681-692.
45. Mukhopadhyay D, Ayaydin F, Kolli N, Tan SH, Anan T, Kametaka A, Azuma Y, Wilkinson KD, Dasso M (2006). SUSP1 antagonizes formation of highly SUMO2/3-conjugated species. J Cell Biol 174, 939-949.
46. Muller S, Matunis MJ, Dejean A (1998). Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 17, 61-70. (Pubitemid 28041048)
47. Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, Pandolfi PP, Dejean A (2005). The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell 9, 769-779.
48. Reineke EL, Kao HY (2009). Targeting promyelocytic leukemia protein: a means to regulating PML nuclear bodies. Int J Biol Sci 5, 366-376.
49. Reverter D, Lima CD (2006). Structural basis for SENP2 protease interactions with SUMO precursors and conjugated substrates. Nat Struct Mol Biol 13, 1060-1068.
50. Rothbauer U, Zolghadr K, Muyldermans S, Schepers A, Cardoso MC, Leonhardt H (2008). A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol Cell Proteomics 7, 282-289.
51. Saitoh H, Hinchey J (2000). Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 275, 6252-6258.
52. Saitoh N, Uchimura Y, Tachibana T, Sugahara S, Saitoh H, Nakao M (2006). In situ SUMOylation analysis reveals a modulatory role of RanBP2 in the nuclear rim and PML bodies. Exp Cell Res 312, 1418-1430.
53. Salomoni P, Pandolfi PP (2002). The role of PML in tumor suppression. Cell 108, 165-170.
54. Schermelleh L et al. (2008). Subdiffraction multicolor imaging of the nuclear periphery with 3D structured illumination microscopy. Science 320, 1332-1336.
55. Schimmel J, Larsen KM, Matic I, van Hagen M, Cox J, Mann M, Andersen JS, Vertegaal AC (2008). The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle. Mol Cell Proteomics 7, 2107-2122.
56. Schwartz DC, Felberbaum R, Hochstrasser M (2007). The Ulp2 SUMO protease is required for cell division following termination of the DNA damage checkpoint. Mol Cell Biol 27, 6948-6961. (Pubitemid 47483642)
57. Sekiyama N, Arita K, Ikeda Y, Hashiguchi K, Ariyoshi M, Tochio H, Saitoh H, Shirakawa M (2010). Structural basis for regulation of poly-SUMO chain by a SUMO-like domain of Nip45. Proteins 78, 1491-1502.
58. Shen LN, Dong C, Liu H, Naismith JH, Hay RT (2006). The structure of SENP1-SUMO-2 complex suggests a structural basis for discrimination between SUMO paralogues during processing. Biochem J 397, 279-288.
59. Shen LN, Geoffroy MC, Jaffray EG, Hay RT (2009). Characterization of SENP7, a SUMO-2/3-specific isopeptidase. Biochem J 421, 223-230.
60. Skilton A, Ho JC, Mercer B, Outwin E, Watts FZ (2009). SUMO chain formation is required for response to replication arrest in S. pombe. PLoS One 4, e6750.
61. Song J, Durrin LK, Wilkinson TA, Krontiris TG, Chen Y (2004). Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci USA 101, 14373-14378.
62. Song J, Zhang Z, Hu W, Chen Y (2005). Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif: a reversal of the bound orientation. J Biol Chem 280, 40122-40129.
63. Stehmeier P, Muller S (2009). Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol Cell 33, 400-409.
64. Sternsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ottmann OG, Ruthardt M (1999). PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 19, 5170-5178.
65. Stuurman N, de Graaf A, Floore A, Josso A, Humbel B, de Jong L, van Driel R (1992). A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. J Cell Sci 101 (Pt 4) 773-784.
66. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT (2008). RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10, 538-546.
67. Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH, Hay RT (2001). Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem 276, 35368-35374.
68. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, Carmo-Fonseca M, Lamond A, Dejean A (1994). Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76, 345-356.
69. Xie SQ, Pombo A (2006). Distribution of different phosphorylated forms of RNA polymerase II in relation to Cajal and PML bodies in human cells: an ultrastructural study. Histochem Cell Biol 125, 21-31.
70. Yuan H, Zhou J, Deng M, Liu X, Le Bras M, de Thé H, Chen SJ, Chen Z, Liu TX, Zhu J (2010). Small ubiquitin-related modifier paralogs are indispensable but functionally redundant during early development of zebrafish. Cell Res 20, 185-196.
71. Yun C, Wang Y, Mukhopadhyay D, Backlund P, Kolli N, Yergey A, Wilkinson KD, Dasso M (2008). Nucleolar protein B23/nucleophosmin regulates the vertebrate SUMO pathway through SENP3 and SENP5 proteases. J Cell Biol 183, 589-595.
72. Zhang FP, Mikkonen L, Toppari J, Palvimo JJ, Thesleff I, Janne OA (2008a). Sumo-1 function is dispensable in normal mouse development. Mol Cell Biol 28, 5381-5390.
73. Zhang H, Saitoh H, Matunis MJ (2002). Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex. Mol Cell Biol 22, 6498-6508.
74. Zhang XD, Goeres J, Zhang H, Yen TJ, Porter AC, Matunis MJ (2008b). SUMO-2/3 modification and binding regulate the association of CENPE with kinetochores and progression through mitosis. Mol Cell 29, 729-741.
75. Zhong S, Muller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP (2000). Role of SUMO-1-modified PML in nuclear body formation. Blood 95, 2748-2752.
76. Zunino R, Braschi E, Xu L, McBride HM (2009). Translocation of SenP5 from the nucleoli to the mitochondria modulates DRP1-dependent fission during mitosis. J Biol Chem 284, 17783-17795.
77. Zunino R, Schauss A, Rippstein P, Andrade-Navarro M, McBride HM (2007). The SUMO protease SENP5 is required to maintain mitochondrial morphology and function. J Cell Sci 120, 1178-1188.